Prospective follow-up study of adalimumab treatment in ankylosing spondylitis: efficacy with focus on uveitis

Phase 4

Recruiting

• Conditions: Ankylosing spondylitis; Bechterew's disease; 10023213

• Registration Number: NL-OMON30515
• Lead Sponsor: Vrije Universiteit Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 18 June 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

Ankylosing spondylitis according to the modified New York criteria, who will start with adalimumab.

Exclusion Criteria

1. Persistent chronic or active infections
2. History of amlignancy
3. Immuno-compromised conditions.
4. History of central nervous system (CNS) demyelinating disease.
5. Female subject who is pregnant or breast-feeding or considering becoming pregnant during the study.
6. Known history of allergic reaction or significant hypersensitivity to the constituents of adalimumab.

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary:<br /><br>- ASAS 20% response<br /><br>- occurrence of attacks of uveitis.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary: adverse events, improvement of mobility, swollen joints,<br /><br>inflammatory markers, and radiographic progression.</p><br>